Our intent in writing the LETTER TO THE EDITOR was to criticize Bryant and Alford's extrapolation from one patient with S aureus endocarditis who clearly relapsed after cefazolin therapy and one who was a very questionable failure to a general prohibition about use of this agent in S aureus endocarditis. We also questioned the validity of their second case and asked for studies of antibacterial activity in serum (usually considered standard procedure in managing endocarditis) to better evaluate their cases. These are not forthcoming in their answer to our letter. We also pointed out that S aureus endocarditis is a difficult disease to treat and that failures have been reported with every antistaphylococcal agent that has been evaluated. We certainly did not question the need to report both favorable and unfavorable results but only their interpretations.
In the preceding letter, Bryant and Alford point out that there is
Kaye D, Hewitt W, Remington JS, Turck M. Treatment of Staphylococcal Endocarditis-Reply. JAMA. 1978;239(12):1130–1131. doi:10.1001/jama.1978.03280390026005
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: